Bortezomib was the first proteasome inhibitor (PI) discovered and demonstrated great efficacy in
myeloma, both in vitro and in patients. However, still many patients ultimately relapse and there is the need for
novel therapies. A second generation of PI have been discovered, potentially more effective ands some also orally
administered. Carfilzomib is an irreversible proteasome inhibitor that showed great efficacy in clinical studies.
Ixazomib is an oral compound that has been introduced recently in the therapeutic spectrum. Novel agents such as
Marizomib seem promising in the fact that can also pass through the blood brain barrier and maybe effective also
in CNS muyeloma. This review focus on all proteasome inhibitors available in clinics and the new ones coming
Keywords: Myeloma, bortezomib, new proteasome inhibitors, carfilzomib, oprozomib.
Rights & PermissionsPrintExport